Announcing Protean’s Partnership with Travera — Protean BioDx
Protean’s new partnership with Travera will bring expanded treatment options to advanced carcinoma patients and their physicians.
Related Articles
How is prostate cancer detected? #prostatecancer #cancerscreening
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Aventa Genomics introduces NGS test for solid tumours
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patients with Solid Cancers
Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
Aventa Genomics introduces NGS test for solid tumours
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome
Cannabis is widely used by patients with cancer to help with cancer symptoms and treatment side effects. Though cannabis has immunomodulatory effects, and its consumption…
Protean BioDiagnostics Partners with Travera to Support Advanced Carcinoma Patients and Their Physicians
/PRNewswire-PRWeb/ — Protean BioDiagnostics is proud to announce its partnership with Travera. As one of Travera’s first Center of Excellence, the partnership…
ChromaCode and Protean to launch assay for lung cancer in US
ChromaCode has entered into a partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.
Protean BioDiagnostics on LinkedIn: Protean is excited to partner with ChromaCode, Inc., to bring innovative…
Protean is excited to partner with ChromaCode, Inc., to bring innovative cancer diagnostic technologies to oncologists and patients!
ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.
/PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and…